New Search

If you are not happy with the results below please do another search

Generic filters

50 search results for:


U.S. CDC backs COVID-19 boosters for high-risk adults, workers, older Americans

The U.S. Centers for Disease Control and Prevention (CDC) on Sept. 24 backed a booster shot of the Pfizer and BioNTech Covid-19 vaccine for Americans aged 65 and older, adults with underlying medical conditions and adults in high-risk working and institutional settings.


WHO backs Regeneron COVID-19 drug cocktail as UN body calls for equal access

A World Health Organization (WHO) panel on Sept. 24 recommended the use of Regeneron and Roche’s Covid-19 antibody cocktail for patients at high risk of hospitalizations and those severely ill with no natural antibodies.


Q&A with CrowdPharm’s Mike Myers and Steve Bernstein

Med Ad News spoke with Mike Myers (managing director and partner of CrowdPharm and managing director and founder of Cross & Wild) and Steve Bernstein (CEO of Bernstein-Rein Advertising and CrowdPharm partner) about the combination of CrowdPharm and Cross & Wild, what makes CrowdPharm different from other agencies, and how they plan to expand the business in the future. 


Two FDA Wins in Two Days for Incyte

Incyte announced Sept. 22 that the Food and Drug Administration approved the company’s Jakafi (ruxolitinib) to treat chronic graft-versus-host disease, one day after the U.S. regulator gave the green light to the cream Opzelura (ruxolinitib) for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis.